Latest news
MedinCell at the 2023 Jefferies Global Healthcare Conference -London, 14-16 November
MedinCell is a clinical- and commercial-stage biopharmaceutical company. We develop a portfolio of long-acting injectables in various therapeutic areas. Our proprietary technology BEPO® aims to ensure patient compliance, improve the effectiveness and accessibility of treatments, and reduce their environmental footprint. We collaborate with tier-one pharmaceutical companies and foundations to improve Global Health through new therapeutic options.
Latest news
MedinCell at the 2023 Jefferies Global Healthcare Conference -London, 14-16 November
Session en français
Rendez-vous le mardi 12 septembre à 18h00 pour la diffusion en direct de l'Assemblée Générale mixte
English session
On Tuesday September 12 at 6:00 p.m. live of the Combined General Meeting (in French)
CONTACT